Genmab A/S (NASDAQ:GMAB) Trading 1.7% Higher - What's Next?

Genmab A/S (NASDAQ:GMAB - Get Free Report) shares traded up 1.7% on Friday . The company traded as high as $21.00 and last traded at $20.93. 160,347 shares changed hands during trading, a decline of 79% from the average session volume of 749,853 shares. The stock had previously closed at $20.58.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GMAB shares. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Morgan Stanley restated an "equal weight" rating and issued a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Truist Financial reduced their price target on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, September 9th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a "buy" rating on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Stock Performance

The business's 50 day moving average price is $21.56 and its 200 day moving average price is $24.54. The firm has a market cap of $13.91 billion, a price-to-earnings ratio of 20.41, a PEG ratio of 0.67 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the prior year, the business posted $0.47 EPS. Sell-side analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently bought and sold shares of the business. Oppenheimer Asset Management Inc. raised its stake in shares of Genmab A/S by 26.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company's stock worth $5,480,000 after buying an additional 45,376 shares during the period. Charles Schwab Investment Management Inc. raised its position in Genmab A/S by 94.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock worth $636,000 after acquiring an additional 12,654 shares during the period. Choreo LLC purchased a new position in Genmab A/S during the second quarter valued at $776,000. Renaissance Technologies LLC grew its position in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock valued at $36,752,000 after purchasing an additional 103,859 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in shares of Genmab A/S in the third quarter valued at about $709,000. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.